|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9000 EUR | -1.10% |
|
-3.43% | +51.01% |
| 11/06 | Triple update for Biosynex |  |
| 11/06 | An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million. | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Diagnostic & Testing Substances
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.91Cr | - | - | - | - | - |
| 1.91TCr | - | ||||
| 977.92Cr | |||||
| 651.06Cr | |||||
| 588.06Cr | - | ||||
| 554.56Cr |
- Stock Market
- Stocks
- ALBIO Stock
- Charts Biosynex
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
